To further enhance tumor infiltration of IL-12 and mitigate systemic toxicity caused by its extratumoral presence, Trani et al.260 engineered mRNAs encoding single-chain IL-12 along with two additional components: a rat anti-mouse AFS98 mAb variable region that targets colony-stimulating factor-1 receptor (CSF1R) and the variable region of Avelumab (anti-PD-L1 antibody), which significantly augment post-transcriptional binding of IL-12 to the tumor. The gene discussed is CSF1R; the disease is neoplasm.